A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Affiliations

• 1 Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
• 2 Division of Hematology/Oncology, Northwestern University, Chicago, Illinois.
• 3 Washington University School of Medicine, Siteman Cancer Center, St Louis, MO.
• 4 Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
• 5 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
• 6 Department of Pathology, The Ohio State University, Columbus, OH.
• 7 Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß.
• 8 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT.
• 9 Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA. william.g.blum@emory.edu.